Navigation Links
Cambrex Receives Notice Regarding NYSE Listing
Date:4/14/2009

ncluding, without limitation, statements regarding expected performance, especially expectations with respect to sales, research and development expenditures, earnings per share, capital expenditures, acquisitions, divestitures, collaborations, or other expansion opportunities. These statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions in connection with any discussion of future financial and operating performance. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout the Company's public filings. Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations including, but not limited to, global economic trends, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation and regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, the Company's ability to satisfy the continued listing standards of the New York Stock Exchange, changes in foreign exchange rates, uncollectible receivables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, and the Company's ability to receive regulatory approvals for its products and other factors described under the caption "Risk Factors That May Affect Future Results" in our annual report on Form 10-K for the year ended December 31, 2008. Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, fu
'/>"/>
SOURCE Cambrex Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. Cambrex Reports Third Quarter 2008 Results
5. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
6. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
9. IsoTis Receives FDA Clearance for Accell Family of Products
10. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
11. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, Inc. ... on gynecologic disease, announced today that investors including ... Birchview Fund LLC and several Vermillion directors have ... shares of Vermillion,s common stock and warrants to ... a private placement.  Under the ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 The ... global leader of technical training across the life sciences ... Data Management (SCDM) to provide the organization's members ... programs —providing access to the more than 350 sessions ... members with 10% off when registering for a ...
(Date:12/22/2014)... 22, 2014  ( www.competitivehealth.com ) — Competitive Health ... bill review and advocacy service, has signed an agreement ... Savings discount health services marketplace. 63% of ... than they expected to pay. As part of an ... WellCard Savings is pleased to offer medical bill review ...
(Date:12/19/2014)... Lawrence, MA (PRWEB) December 19, 2014 ... flow MRLAFMQ test for the Detection of Aflatoxin M1 ... test to receive independent third party validation. The peer ... Science Unit of the Institute for Agricultural and Fisheries ... Francis Group. , Aflatoxin B1, the most toxic ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... SAN DIEGO, May 9, 2011 Ardea Biosciences, Inc. ... on the development of small-molecule therapeutics for the treatment ... results for the first quarter ended March 31, 2011. ... lesinurad in combination with allopurinol demonstrate lesinurad,s potential to ...
... 9, 2011 Cell Biosciences, Inc. today announced the ... Patent and Trademark Office, Patent Nos. 7,935,489, 7,935,308 and ... Cell Biosciences, NanoPro™ Assay Technology. NanoPro assay systems utilize ... high-sensitivity measurement of specific proteins in complex biological samples. ...
... May 9, 2011 BD Diagnostics, a segment of ... (NYSE: BDX ), and Diagenode SA, an ... agreement to co-develop seven initial molecular diagnostic assays on ... enteric and central nervous system diseases.   ...
Cached Biology Technology:Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 2Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 3Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 4Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 5Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 6BD and Diagenode Collaborate to Expand Infectious Disease Menu on the BD MAX™ System 2BD and Diagenode Collaborate to Expand Infectious Disease Menu on the BD MAX™ System 3BD and Diagenode Collaborate to Expand Infectious Disease Menu on the BD MAX™ System 4
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/10/2014)... NEW YORK , Dec. 8, 2014 You,ve ... online banking account but can,t remember your password, site key ... birthday? Who was your first grade teacher? ... launches the app that will finally put an ... PINs – 1U TM . 1U leverages a ...
(Date:12/10/2014)... 9, 2014 CIE San Diego has launched ... the connective tissue that enhances care coordination among social ... share client-level information; earned a second $1 million grant ... serving seniors aging in community and; will be recognized ... 11 th 4-6p. CIE San Diego ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... journal called Air Quality, Atmosphere and Health. The ... of research in this rapidly developing area. Scheduled ... environmental and public health publishing portfolio. Air Quality, ... focus on the atmospheric consequences of human activity and ...
... demonstrates that the use of an acute, localized static ... reduction of swelling when applied immediately after an inflammatory ... engineering, and Cassandra Morris, a former Ph.D. student in ... November 2007 edition of the American Journal of Physiology. ...
... study investigating the carbon sink capacity of northern ... net carbon uptake period (CUP) has on average ... carbon uptake of northern ecosystems is decreasing in ... published January 3rd, in the journal Nature. The ...
Cached Biology News:Springer founds new journal Air Quality, Atmosphere and Health 2UVa biomedical engineering study shows magnetic field can reduce swelling 2UVa biomedical engineering study shows magnetic field can reduce swelling 3
Goat polyclonal to Sarcosine Oxidase (HRP) ( Abpromise for all tested applications). Antigen: Full length protein: Sarcosine Oxidase (microbial). Entrez Gene ID: 51268 Swiss Protein ID: ...
Rabbit monoclonal [E227] to ZAP70 (phospho Y319) ( Abpromise for all tested applications). Antigen: Synthetic phospho peptide corresponding to residues surrounding Tyr319 of human ZAP70 Entre...
...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
Biology Products: